Literature DB >> 3462243

Urinary excretion of 6-keto-prostaglandin F1 alpha, thromboxane B2 and prostaglandin E2 in cirrhosis with ascites. Relationship to functional renal failure (hepatorenal syndrome).

A Rimola, P Ginés, V Arroyo, J Camps, R M Pérez-Ayuso, E Quintero, J Gaya, F Rivera, J Rodés.   

Abstract

The aim of the study was to investigate the urinary excretion of 6-keto-PGF1 alpha (a stable metabolite of PGI2), thromboxane B2 (TxB2; a stable metabolite of TxA2), and PGE2 in 18 normal subjects, 49 cirrhotics with ascites without renal failure (GFR = 90 +/- 4 ml/min, means +/- S.E.M.) and 20 cirrhotics with functional renal failure (FRF) (GFR = 36 +/- 3). The study was made after 5 days on a 50 mEq sodium diet and without diuretics. Plasma renin activity (PRA), plasma norepinephrine concentration (NE) and plasma antidiuretic hormone concentration (ADH) were also measured. Cirrhotics without FRF showed a significantly higher urinary excretion of 6-keto-PGF1 alpha, TxB2 and PGE, (15.9 +/- 1.7 ng/h, 3.0 +/- 0.3 ng/h, and 6.2 +/- 1.0 ng/h) than did normal subjects (9.2 +/- 0.9, 1.3 +/- 0.1 and 2.3 +/- 0.4). On the contrary, the urinary excretion of these prostaglandins was normal or reduced in patients with FRF (5.3 +/- 0.8, 1.3 +/- 0.2 and 1.9 +/- 0.4). PRA, NE and ADH were significantly increased in cirrhotics with FRF (15.2 +/- 3.9 ng/ml/h, 1026 +/- 149 pg/ml and 4.1 +/- 0.3 pg/ml) and in patients without FRF (8.0 +/- 1.4, 667 +/- 67 and 3.9 +/- 0.3) as compared to normal controls (1.3 +/- 0.2, 275 +/- 46 and 2.4 +/- 0.2). These results suggest that renal hemodynamics in cirrhosis depends upon a critical equilibrium between the activity of endogenous vasoconstrictor systems and the renal production of the vasodilator prostaglandins PGI2 and PGE2. In addition, they do not support FRF in cirrhosis being related to an increased renal production of the vasoconstrictor prostaglandin TxA2.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3462243     DOI: 10.1016/s0168-8278(86)80154-4

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  12 in total

Review 1.  The hepatorenal syndrome.

Authors:  L Dagher; K Moore
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

2.  Eicosanoid excretion in hepatic cirrhosis. Predominance of 20-HETE.

Authors:  D Sacerdoti; M Balazy; P Angeli; A Gatta; J C McGiff
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

3.  Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man?

Authors:  R Jalan; E H Forrest; D N Redhead; J F Dillon; P C Hayes
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

Review 4.  Pathogenesis of ascites and hepatorenal syndrome.

Authors:  S P Wilkinson; K P Moore; V Arroyo
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

5.  Urinary thromboxane B2 as an indicator of acute rejection in human liver transplantation.

Authors:  H Isozaki; O Farges; D Samuel; R Adam; H Bismuth
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

Review 6.  Management of hepatorenal syndrome.

Authors:  Halit Ziya Dundar; Tuncay Yılmazlar
Journal:  World J Nephrol       Date:  2015-05-06

7.  Loss of tubuloglomerular feedback in decompensated liver cirrhosis: physiopathological implications.

Authors:  Giovanni Sansoè; Stefano Silvano; Giulio Mengozzi; Antonina Smedile; Giovanni Touscoz; Floriano Rosina; Mario Rizzetto
Journal:  Dig Dis Sci       Date:  2005-05       Impact factor: 3.199

8.  A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.

Authors:  Arun J Sanyal; Thomas Boyer; Guadalupe Garcia-Tsao; Frederick Regenstein; Lorenzo Rossaro; Beate Appenrodt; Andres Blei; Veit Gülberg; Samuel Sigal; Peter Teuber
Journal:  Gastroenterology       Date:  2008-02-13       Impact factor: 22.682

Review 9.  The hepatorenal syndrome.

Authors:  G Van Roey; K Moore
Journal:  Pediatr Nephrol       Date:  1996-02       Impact factor: 3.714

Review 10.  Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications.

Authors:  Csaba Matyas; György Haskó; Lucas Liaudet; Eszter Trojnar; Pal Pacher
Journal:  Nat Rev Cardiol       Date:  2020-09-30       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.